CureVac settles a long-running patent dispute over mRNA vaccines with Pfizer and BioNTech in the US https://t.co/8J44Hlq9XY ...

Public Health Concerns - Former Surgeon General Jerome Adams criticizes the decision to cancel nearly $500 million in mRNA vaccine contracts, stating it will cost lives [1] - Public health experts express alarm, with one expert calling it the most dangerous public health judgment in 50 years [2] mRNA Vaccine Efficacy and Alternative Approaches - The head of HHS suggests mRNA vaccines don't perform well against upper respiratory tract viruses and may encourage mutations [3] - Dr Gupta clarifies mRNA vaccines are designed to protect the lower respiratory tract (lungs) from severe disease, not prevent upper respiratory tract infections [5][6][7] - Whole virus vaccines, while an alternative, are less effective, cause more side effects, and take 10-15 years to develop, making mRNA a faster option for pandemic threats [8] Communication and Public Perception - The biggest challenge is breaking through to a population not versed in scientific terms, as traditional entities are not nimble on social media where controversial narratives gain traction [9][10] - Fundamental mistruths about mRNA technology, such as altering genetic profiles, are easily spread, creating narratives that are difficult to counter [11][12]

Vaccine Development - NIH is developing a universal vaccine that mimics natural immunity, potentially effective against various mutations, including coronaviruses and flu [1][2] - mRNA vaccines may be useful for some illnesses, including cancers, but trials for upper respiratory infections were cancelled [1] Political Implications - Extremist views on both sides regarding COVID-19 vaccines may alienate moderate voters [3][4] - Gutting funding for vaccine development could confuse middle America voters who saw the COVID-19 vaccine as a good idea [4]

RT Alex Knapp (@TheAlexKnapp)ICYMI, there was a ton of science and tech news in last week's edition of The Prototype, including mRNA vaccines to fight HIV, major sources of water for Martian colonists and more. Subscribe so you don't miss the next one!https://t.co/OkHSobK40ihttps://t.co/p7FvpsRRmO ...

Core Viewpoint - Investing in stocks priced under $30 can yield significant returns, with Pfizer and Adyen identified as two promising options for investors [2]. Group 1: Pfizer - Pfizer's stock has declined from approximately $60 per share in late 2021 to just under $22, primarily due to reduced sales from its COVID-19 portfolio and upcoming patent cliffs, including Eliquis [3][4]. - Despite recent challenges, Pfizer has developed a robust pipeline, particularly in oncology, which is expected to yield significant clinical and regulatory successes in the near future [4]. - The company has shown resilience in its financial performance, with ongoing contributions from its coronavirus products and a strong dividend yield of 7.8%, appealing to income-focused investors [7][8]. Group 2: Adyen - Adyen, a Netherlands-based fintech, offers integrated payment solutions that are essential for multinational companies, boasting clients like Microsoft, Uber, and Spotify [9]. - The company's stock has experienced volatility due to economic challenges affecting transaction volumes and its decision to maintain spending, which impacted margins [10]. - Adyen's strong customer retention due to switching costs and the ongoing shift to e-commerce present significant growth opportunities, making its shares, priced under $16, an attractive investment [11].